Dianthus Therapeutics' (DNTH) Buy Rating Reaffirmed at Guggenheim

Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) in a research report report published on Wednesday morning,Benzinga reports. Guggenheim currently has a $84.00 target price on the stock.

A number of other equities research analysts also recently issued reports on DNTH. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a research note on Friday, December 20th. They issued a "buy" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday. Finally, Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

DNTH traded up $0.05 during trading on Wednesday, hitting $21.33. The company's stock had a trading volume of 167,735 shares, compared to its average volume of 226,600. The firm has a market capitalization of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82. Dianthus Therapeutics has a twelve month low of $18.13 and a twelve month high of $33.77. The business's fifty day simple moving average is $22.61 and its 200 day simple moving average is $24.92.

Remove Ads

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million. As a group, equities research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. TCG Crossover Management LLC purchased a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $32,735,000. Braidwell LP boosted its holdings in Dianthus Therapeutics by 144.4% in the fourth quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares during the last quarter. Vestal Point Capital LP boosted its stake in Dianthus Therapeutics by 172.2% during the 4th quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company's stock valued at $23,435,000 after acquiring an additional 680,000 shares during the last quarter. State Street Corp grew its stake in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company's stock worth $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its stake in Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock valued at $46,002,000 after purchasing an additional 363,500 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.